Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDaniel D. Von Hoff, Markus F. Renschler, Josep Tabernero et al.|New England Journal of Medicine|2013Cited by 6.6k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerTalia Golan, Hedy L. Kindler, Pascal Hammel et al.|New England Journal of Medicine|2019Cited by 2.2k
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trialMarkus Joerger, Andrés J.M. Ferreri, A. D. R. Huitema et al.|British Journal of Cancer|2010Cited by 85
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.Talia Golan, Hedy L. Kindler, Pascal Hammel et al.|Journal of Clinical Oncology|2021Cited by 78